The Chemours
CC
The Chemours (CC) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.42
- EPS estimate
- $0.50
- EPS surprise
- −15.39%
- Revenue surprise
- −3.84%
- Revenue
- $1.6B
- Revenue estimate
- $1.7B
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.50 | $0.42 | −15.39% | $1.6B | SEC |
| Q1 2026 | May 5, 2026 | −$0.04 | $0.05 | +227.23% | $1.4B | SEC |
| Q4 2025 | Feb 19, 2026 | $0.07 | $0.05 | −31.22% | $1.3B | SEC |
| Q3 2025 | Nov 6, 2025 | $0.24 | $0.20 | −15.90% | $1.5B | SEC |
| Q2 2025 | Aug 5, 2025 | $0.46 | $0.58 | +27.14% | $1.6B | SEC |
| Q1 2025 | May 6, 2025 | $0.20 | $0.13 | −33.84% | $1.4B | SEC |
| Q4 2024 | Feb 18, 2025 | $0.12 | $0.11 | −9.24% | $1.4B | SEC |
| Q3 2024 | Nov 4, 2024 | $0.29 | $0.40 | +40.25% | $1.5B | SEC |
| Q2 2024 | Aug 1, 2024 | $0.57 | $0.38 | −33.50% | $1.5B | SEC |
| Q1 2024 | Apr 30, 2024 | $0.18 | $0.32 | +76.60% | $1.4B | SEC |
| Q4 2023 | Feb 29, 2024 | $0.27 | $0.31 | +15.24% | $1.4B | SEC |
| Q3 2023 | Oct 26, 2023 | $0.69 | $0.63 | −8.44% | $1.5B | SEC |
| Q2 2023 | Jul 28, 2023 | $1.08 | $1.10 | +1.93% | $1.6B | SEC |
| Q1 2023 | Apr 27, 2023 | $0.46 | $0.98 | +113.51% | $1.5B | SEC |
| Q4 2022 | Feb 9, 2023 | $0.10 | $0.00 | −100.00% | $1.3B | SEC |
| Q3 2022 | Oct 25, 2022 | $1.04 | $1.24 | +18.80% | $1.8B | SEC |
| Q2 2022 | Jul 28, 2022 | $1.41 | $1.89 | +34.13% | $1.9B | SEC |
| Q1 2022 | May 2, 2022 | $0.91 | $1.46 | +59.63% | $1.8B | SEC |
| Q4 2021 | Feb 10, 2022 | $0.89 | $0.81 | −8.71% | $1.6B | SEC |
| Q3 2021 | Nov 4, 2021 | $1.01 | $1.27 | +26.29% | $1.7B | SEC |
Quarterly revenue
Frequently asked questions
When did The Chemours (CC) last report earnings?
The Chemours last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did CC beat earnings estimates?
No. The Chemours reported EPS of $0.42 for Q2 2026 against a $0.50 estimate — a 15.39% miss.
How much revenue did CC report last quarter?
The Chemours reported $1.6B in revenue for Q2 2026, against a consensus estimate of $1.7B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.